
BIOGRAPHICAL SKETCH

| | |
|---|--|
| NAME Silvia Cristina Sookoian | POSITION TITLE Head of the Clinical & Molecular Hepatology Department. CONICET (National Scientific and Technical Research Council) & Center for Advanced Studies in Human and Health Sciences (CAECIHS), Inter-American Open University. Buenos Aires. Argentina |
| eRA COMMONS USERNAME (credential, e.g., agency login) SILVIASOOKOIAN | |
| E-mail: ssookoian@intramed.net Mobile: 5491164556419 | Deputy Director. Center for Advanced Studies in Human and Health Sciences (CAECIHS), Inter-American Open University. Buenos Aires. Argentina |
| | Dean of the Faculty of Medical Science. Maimonides University. Buenos Aires. Argentina. |

CURRENT ADDRESS:

CAECIHS UAI-CONICET Av. Montes de Oca 745, (1270AAH) Buenos Aires, Argentina

Maimonides University: Hidalgo 775 (C1405BCK) Buenos Aires, Argentina

E-mail: sookoian.silvia@maimondies.edu

Website: https://www.conicet.gov.ar/new_scp/detalle.php?id=22756&keywords=Sookoian&datos_academicos=yes

EDUCATION/TRAINING (*Begin with baccalaureate or other initial professional education, such as nursing, include postdoctoral training and residency training if applicable.*)

| INSTITUTION AND LOCATION | DEGREE | MM/YY | FIELD OF STUDY |
|---|-------------------------------|-----------------|--|
| University of Buenos Aires, School of Medicine | MD (<i>magna cum laude</i>) | 12/1986 | Medicine |
| University of Buenos Aires, School of Medicine | Ph.D. | 03/2000 | Medicine |
| University of Buenos Aires, School of School of Exact and Natural Sciences | Master | 12/2001 | Molecular Medicine |
| National University of Lanus | Specialist | 12/2000 | Methodology of the Scientific Research |
| Argerich Hospital Associated to University of Buenos Aires. Government of City of Buenos Aires. Argentina | Residency and Chief residency | 01/1987-06/2001 | Internal Medicine |

MEDICAL LICENSURE: Medical licensure in the Argentinean Republic

EXAMINATION: Board Certified in Internal Medicine 2002

A. Personal Statement

She has a position as a physician scientist devoted to translating scientific knowledge in Hepatology into the patients care. Her current clinical and translational research is focused on genetic, epigenetic, and molecular mechanisms implicated in non-alcoholic fatty liver disease (NAFLD) pathogenesis and disease progression. Dr. Sookoian has published extensively in the field of Liver Diseases, including NAFLD and hepatitis C. She has been in clinical practice since 1987 (Clinical Training Board certificated in Internal Medicine; Fellowship in Hepatology). She received training in Hepatology (Karolinska Institute, Huddinge University Hospital. Sweden. 1997: Hepatology Centers of Excellence Program; pathology (Armed Forces Institute of Pathology. Washington DC. 2000); genetics of complex diseases (Cold Spring Harbor Laboratories. NY, USA, and Wellcome Trust Advanced Courses 2006).

B. Positions and Honors

ACADEMIC APPOINTMENTS

Staff Researcher. National Scientific and Technical Research Council (CONICET). 2003-Current. Category: Senior Investigator. <http://www.conicet.gov.ar>. Buenos Aires. Argentina. CONICET is the main government agency that fosters the development of science and technology in Argentina. This Career comprises five categories (Assistant, Associate, Independent, Principal and Senior).

PROFESSIONAL APPOINTMENTS:

Head, Department of Clinical & Molecular Hepatology. Institute of Medical Research (Instituto de Investigaciones Medicas), IDIM-CONICET. School of Medicine, University of Buenos Aires. 2003-September 2022

Vice Chair for Institute of Medical Research (Instituto de Investigaciones Medicas), IDIM-CONICET, School of Medicine, University of Buenos Aires. 2015-December 2021.

Head of the Clinical & Molecular Hepatology Department. CONICET (National Scientific and Technical Research Council) & Center for Advanced Studies in Human and Health Sciences (CAECIHS), Inter-American Open University. Buenos Aires. Argentina. October 2022-current

Deputy Director. Center for Advanced Studies in Human and Health Sciences (CAECIHS), Inter-American Open University. Buenos Aires. Argentina. October 2022-current

Dean of the Faculty of Medical Science. Maimonides University. Buenos Aires. Argentina. March 2023-current.

SERVICE TO PROFESSIONAL ORGANIZATIONS:

National Organizations

1. Chairman of the Session: Clinical Science and Public Health Commission, for the evaluation of National Research Funding. National Agency Scientific and Technical Research (Agencia Nacional de Promoción Científica y Tecnológica. ANACYT-Foncyt). Argentina. 2010-2013.
2. Permanent member Roster Commission Research & Development (PID-Clinic) The Fund for Scientific and Technological Research (FONCYT). 2013-2015
3. Coordinator of the Sentinel Unit of the National Program of Viral Hepatitis Surveillance. Ministry of Public Health. Buenos Aires Argentina. 1992-2000.
4. Member of the Adviser Group of the National Program of Viral Hepatitis Surveillance. Ministry of Health. Buenos Aires. Argentina 1994-2000

International Organizations (EVALUATION OF RESEARCH/INVESTIGATORS)

1. REA-FP7-HEALTH. European Commission. Research Executive Agency. 2012-2013
Medical Research Council United Kingdom. 2012-2016
2. Medical Research Council South Africa. 2012-2012
3. Israel Science Foundation. 2010- 2013
4. Research Grant Council (RGC) of Hong Kong. 2012-2016
5. National Institute of Health Extramural Review Branch. National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK). 2013
6. National Institute of Diabetes, Digestive, and Kidney Diseases at the National Institutes of Health. 2018
7. Estonian Research Council (ETAg). 2018-2021.
8. SC1-BHC-18-2018: Translational collaborative cancer research between Europe and the Community of Latin American and Caribbean States (CELAC). European Commission Horizon 2020. 2018.-Expert (member Consensus Panel)
9. The Wellcome Trust DBT India Alliance Fellowship. 2018.
10. European Commission call Topic SC1-BHC-08-2020 stage I. Health, Demographic Change and Wellbeing' challenge under Horizon 2020 – Topic SC1-BHC-08-2020: New therapies for Non-Communicable Diseases. 2019. Brussels, Belgium.
11. Health, Demographic Change and Wellbeing' challenge under Horizon 2020 – Topic SC1-BHC-08-2020: New therapies for Non-Communicable Diseases. Brussels, Belgium
12. European Commission call SC1-BHC-17-2020 stage II: member of the Consensus Panel. SC1-BHC-17-2020: Global Alliance for Chronic Diseases (GACD) 2 - Cancer prevention and early detection. Virtual session 2020.
13. Department of Internal Medicine-Gastroenterology, Medical School at the University of Michigan. 2020. Evaluation of investigators promotion.

14. National Institute of Diabetes, Digestive, and Kidney Diseases at the National Institutes of Health, 2021. Evaluation of investigators promotion.
15. Expert European Commission Horizon Europe Cluster 1 Health - Topic: HORIZON-HLTH-2022-DISEASE-06-04-two-stage Development of new effective therapies for rare diseases. 2022
16. Expert Horizon Europe Cluster 1 Health - Topic: HORIZON-MISS-2021-CANCER-02. 2022
17. European Commission call Horizon Europe. Monitor Project A-TANGO – 945096

Professional Service (International) to Editorial board of International Journals

1. Editorial board member GUT Country: UK (2015- current)
2. Editorial board member HEPATOLOGY Country USA (2016-2021)
3. Editorial board member Journal of Lipid Research Country: USA (2019-current)
4. International Editorial Board Journal of Alimentary Pharmacology & Therapeutics. Country: UK (2020-current)
5. Editorial board member Liver International. Country: UK (2020- current)
6. Editorial board member Hepatobiliary Surgery and Nutrition (HBSN) Country: CHINA (2020-current)
7. Deputy Editor, Hepatobiliary Surgery and Nutrition (HBSN) Country: CHINA (2021-current)
8. Editorial Advisory Panel Clinical Science Country UK (2012-2015)
9. PlosOne Academic Editor Country USA (2012-current)
10. World Journal of Gastroenterology. Country China, 2008-2013
11. Annals of Hepatology. 2002-2006. Country Mexico.

Professional Service (International) to AASLD

1. Program Chair SIG NAFLD-ALD: NAFLD and ALD in the Era of Integrative OMICS and Precision Medicine. Liver Meeting 2016. AASLD. Boston USA.
2. Member of the PROGRAM EVALUATION COMMITTEE American Association for the Study of Liver Disease (AASLD). 2010-2013.
3. Member of the Steering Committee Steatosis and Steatohepatitis Special Interest Group of AASLD and Co-Chair of its global outreach subcommittee (2018-2020).
4. Member of the Latin American Regional Advisory Council of AASLD (2019-current).
5. Abstract review committee American Association for the Study of Liver Diseases (AASLD) Steatosis and Steatohepatitis: Clinical and Therapeutic. Liver Meeting (2015-2019)
6. Abstract review committee American Association for the Study of Liver Diseases (AASLD) Steatosis and Steatohepatitis: Clinical and Therapeutic. DDW (2016-2019)
7. Moderator of the Session: *Genetic Modifiers in NAFLD*. 63rd Annual Meeting of the American Association for the Study of Liver Diseases. Boston USA 2012.
8. Moderator of the Session: Parallel Session: *NASH: Diagnosis and Treatment*. The Liver Meeting 2013 in Washington, DC, November 1-5.
9. Moderator of the Session: Parallel Session Session Title: Parallel 35: *Fatty Liver Disease: Clinical and Therapeutic II*. Date: November 17, 2015. The Liver Meeting 2015 in San Francisco, CA November 13 - 17.
10. Moderator of the Session: *ASH/NASH: Clinical Session Type: Topic Forum*. Digestive Disease Week 2016. San Diego, USA 2016.
11. Moderator of the Session: Parallel 5: *NAFLD: Diagnosis and Natural History*
Date: November 13, 2016. The Liver Meeting® 2016 in Boston, MA November 11 - 15. Annual Meeting of the American Association for the Study of Liver Diseases. Boston USA 2016
12. Moderator of *Steatosis and Steatohepatitis SIG Program*. The Liver Meeting 2016 in Boston, MA November 11 - 15. Annual Meeting of the American Association for the Study of Liver Diseases. Boston USA 2016
13. Moderator of the Session: Parallel 6: *Novel Therapeutics for NASH*. The Liver Meeting 2019 Annual Meeting of the American Association for the Study of Liver Diseases. Boston USA
14. Abstract review committee American Association for the Study of Liver Diseases (2016-2019)
15. Review Chair. American Association for the Study of Liver Diseases. NAFLD and NASH clinical. Liver Meeting 2021-2022.
16. Program Chair SIG NAFLD 2021. Precision medicine in evaluation and treatment of NAFLD. American Association for the Study of Liver Diseases
17. Member of the NAFLD Nomenclature Steering Committee
18. Jury for the 2022 Innovators in Science Award in Gastroenterology. Innovators in Science Awards. New York Academy of Sciences.
19. Review Session Chair. American Association for the Study of Liver Diseases. NAFLD and NASH clinical. Liver Meeting 2023. DDW 2023.

Professional Service (International) to other Societies

- Abstract review committee UEG Week (2013- 2018)
 Abstract review committee American Society of Nutrition (2018)

Honors

Fellow of the American Association for the Study of the Liver Disease (AASLD). Elected 2016.

International awards (selected)

MSD Young Investigator Award. The XVIth Scientific Meeting of the Inter-American Society of Hypertension. THE SHORT VARIANT OF THE SEROTONIN TRANSPORTER GENE (SLC6A4) IS AN INDEPENDENT RISK FACTOR FOR OBESITY IN ADOLESCENTS WITH METABOLIC SYNDROME.

Council For High Blood Pressure Research, American Heart Association. Latin American investigator award. Title: Genetic Variants Of Clock Transcription Factor Are Associated With Susceptibility To Obesity And Hypertension In Individuals With Metabolic Syndrome. InterAmerican Society of Hypertension, 2007.

C. Selected Peer-reviewed Publications (Selected from 190 peer-reviewed Pubmed indexed publications)

ORCID ID: <http://orcid.org/0000-0001-5929-5470>. Scopus h-index 51/scholar h-index 58.

Contributions to Science

Early publications from my group directly addressed the topic of the pathogenesis of NAFLD and the role of genetic and epigenetic factors in the disease progression. More recently we described for the very first time the metataxonomic profiling of the liver tissue in patients with NAFLD and the importance of the tissue microbiota in the disease severity. Our group have been using several OMICs techniques to uncover key aspects of NAFLD biology, including transcriptomics, genomics, epigenomics, and metagenomics.

- COVID-19 and NAFLD: biological insights from multi-omics data. Pirola CJ, **Sookoian S**. Liver Int. 2023 Jan 2. doi: 10.1111/liv.15509. Online ahead of print. PMID: 36593576
- PNPLA3 rs738409 and risk of fibrosis in NAFLD: Exploring mediation pathways through intermediate histological features. Vilar-Gomez E, Pirola CJ, **Sookoian S**, Wilson LA, Liang T, Chalasani N. Hepatology. 2022 Nov;76(5):1482-1494.
- The influence of host genetics on liver microbiome composition in patients with NAFLD. Pirola CJ, Salatino A, Quintanilla MF, Castaño GO, Garaycochea M, **Sookoian S**. EBioMedicine. 2022 Feb;76:103858. doi: 10.1016/j.ebiom.2022.
- Liver Mitochondrial DNA Damage and Genetic Variability of Cytochrome B - A Key Component of the Respirasome - Drive the Severity of Fatty Liver Disease. Pirola CJ, Garaycochea M, Flichman D, Castaño GO, **Sookoian S**. **J Intern Med.** 2021 Jan;289(1):84-96
- Intrahepatic bacterial metataxonomic signature in non-alcoholic fatty liver disease. **Sookoian S**, Salatino A, Castaño GO, Landa MS, Fijalkowky C, Garaycochea M, Pirola CJ. **Gut.** 2020 Aug;69(8):1483-1491
- Impact of the Association Between PNPLA3 Genetic Variation and Dietary Intake on the Risk of Significant Fibrosis in Patients With NAFLD. Vilar-Gomez E, Jose Pirola C, **Sookoian S**, Wilson LA, Belt P, Liang T, Liu W, Chalasani N. **Am J Gastroenterol.** 2020 Dec 10. doi: 10.14309/ajg.0000000000001072.
- ADH1B*2 is Associated With Reduced Severity of Nonalcoholic Fatty Liver Disease in Adults, Independent of Alcohol Consumption. Vilar-Gomez Eduardo, **Sookoian Silvia**, Pirola Carlos Jose, Liang Tiebing, Gawrieh Samer, Cummings Oscar, Liu Wanqing, Chalasani Naga. **Gastroenterology** 2020 Sep;159(3):929-943.
- SARS-CoV-2 virus and liver expression of host receptors: Putative mechanisms of liver involvement in COVID-19. Pirola CJ, **Sookoian S**. **Liver Int.** 2020;40(8):2038-2040
- COVID-19 and ACE2 in the liver and gastrointestinal tract: Putative biological explanations of sexual dimorphism. Pirola CJ, **Sookoian, S**. **Gastroenterology.** 2020 Oct;159(4):1620-1621
- Splice variant rs72613567 prevents worst histologic outcomes in patients with nonalcoholic fatty liver disease. Pirola CJ, Garaycochea M, Flichman D, Arrese M, San Martino J, Gazzi C, Castaño GO, **Sookoian S**. **J Lipid Res.** 2019 Jan;60(1):176-185.
- Genetic variation in Long noncoding RNAs and the risk of Nonalcoholic Fatty Liver Disease. Silvia Sookoian, Cristian Rohr, Adrián Salatino, Hernán Dopazo, Tomas Fernandez Gianotti, Gustavo Castaño, Carlos Pirola. **Oncotarget.** 2017;8(14):22917-22926.
- Mitochondrial genome architecture in non-alcoholic fatty liver disease. Sookoian S, Flichman D, Scian R, Rohr C, Dopazo H, Fernández Gianotti T, San Martino J, Castaño GO, Pirola CJ. **J Pathol.** 2016;240(4):437-449.
- Serum aminotransferases in nonalcoholic fatty liver disease are a signature of liver metabolic perturbations at the amino acid and Krebs cycle level. Sookoian S, Castano G, Scian R, Gianotti T, Dopazo H, Rohr C, Gaj G, San Martino J, Sevic I, Flichman D, Pirola CJ. **Am J Clin Nutr** 2016;103:1-14.
- Metabolite Signatures of Metabolic Risk Factors and their Longitudinal Changes. Xiaoyan Yin, Subha Subramanian, Christine M. Willinger, Peter Juhasz, Paul Courchesne, Brian H. Chen, Xiaohang Li, Shih-Jen Hwang, Caroline S. Fox, Christopher J. O'Donnell, Pieter Muntendam, Valentin Fuster, Ivana Bobeldijk-Pastorova, Silvia C. Sookoian, Carlos J. Pirola, Neal Gordon, Aram Adourian, Martin G. Larson, Daniel Levy. **The Journal of Clinical Endocrinology & Metabolism.** 2016 Apr;101(4):1779-89.

- Mendelian randomisation suggests no beneficial effect of moderate alcohol consumption on the severity of nonalcoholic fatty liver disease. Sookoian S, Flichman D, Castaño GO, Pirola CJ. **Aliment Pharmacol Ther.** 2016 Dec;44(11-12):1224-1234
- Genetic Variation in *TM6SF2* and the Risk of Nonalcoholic Fatty Liver Disease and Histological Disease Severity. Sookoian S, Castaño GO, Scian R, Mallardi P, Fernández Gianotti T, Burgueño AL, San Martino J, and Pirola CJ. **Hepatology** 2015; 61(2):515-25.
- Circulating microRNA signature in non-alcoholic fatty liver disease: from serum non-coding RNAs to liver histology and disease pathogenesis. Pirola CJ, Fernández Gianotti T, Castaño GO, Mallardi P, San Martino J, Mora Gonzalez Lopez Ledesma M, Flichman D, Mirshahi F, Sanyal AJ, Sookoian S. **GUT** 2015 May;64(5):800-12.
- Epigenetic modification of liver mitochondrial DNA is associated with histological severity of nonalcoholic fatty liver disease. Pirola CJ, Fernández Gianotti T, Burgueño AL, Rey-Funes M, Loidl CF, Mallardi P, San Martino J, Castaño GO, Sookoian S. **Gut.** 2013;62(9):1356-63.
- Meta-analysis of the influence of I148M variant of patatin-like phospholipase domain containing 3 gene (PNPLA3) on the susceptibility and histological severity of nonalcoholic fatty liver disease. Sookoian S, Pirola CJ. **Hepatology.** 2011 Jun;53(6):1883-94.
- Epigenetic regulation of insulin resistance in nonalcoholic fatty liver disease: impact of liver methylation of the peroxisome proliferator-activated receptor γ coactivator 1 α promoter. Sookoian S, Rosselli MS, Gemma C, Burgueño AL, Fernández Gianotti T, Castaño GO, Pirola CJ. **Hepatology.** 2010, 52(6):1992-2000.
- Loci from a genome-wide analysis of bilirubin levels are associated with gallstone risk and composition. Buch S, Schafmayer C, Völzke H, Seeger M, Miquel JF, Sookoian SC, Egberts JH, Arit A, Pirola CJ, Lerch MM, John U, Franke A, von Kampen O, Brosch M, Nothnagel M, Kratzer W, Boehm BO, Brüning DC, Schreiber S, Krawczak M, Hampe J. **Gastroenterology.** 2010;139(6):1942-1951.
- A nonsynonymous gene variant in the adiponutrin gene is associated with nonalcoholic fatty liver disease severity. Sookoian S, Castaño GO, Burgueño AL, Gianotti TF, Rosselli MS, Pirola CJ. **J Lipid Res.** 2009;50(10):2111-6.
- A1166C angiotensin II type 1 receptor gene polymorphism may predict hemodynamic response to losartan in patients with cirrhosis and portal hypertension. Sookoian S, Castaño G, García SI, Viudez P, González C, Pirola CJ **Am J Gastroenterol.** 2005;100(3):636-42.

EDITORIALS & REVIEWS

- Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease. Åberg F, Byrne CD, Pirola CJ, Männistö V, **Sookoian S.** *J Hepatol.* Jan;78(1):191-206
- Genetics in non-alcoholic fatty liver disease: The role of risk alleles through the lens of immune response. **Sookoian S,** Pirola CJ. *Clin Mol Hepatol.* doi: 10.3350/cmh.2022.0318. Online ahead of print
- Geographical similarity and differences in the burden and genetic predisposition of NAFLD. Yip TC, Vilar-Gomez E, Petta S, Yilmaz Y, Wong GL, Adams LA, de Ledinghen V, **Sookoian S,** Wong VW. *Hepatology.* 2022 Sep 5. doi: 10.1002/hep.32774. Online ahead of print. PMID: 36062393
- The lipidome in nonalcoholic fatty liver disease: Actionable targets. Pirola CJ, **Sookoian S.** *J Lipid Res.* 2021 Apr 9:100073. doi: 10.1016/j.jlr.2021.100073.
- NAFLD and Cardiometabolic Risk Factors: The Liver Fibrosis Trajectory Through the Lens of Biological Interactions. Pirola CJ, **Sookoian S.** *Hepatology.* 2021;73(2):479-482
- Genetic pathways in nonalcoholic fatty liver disease: Insights from systems biology. **Sookoian S,** Pirola CJ, Valenti L, Davidson NO. **Hepatology.** 2020 Jul;72(1):330-346.
- MAFLD: A Consensus-Driven Proposed Nomenclature for Metabolic Associated Fatty Liver Disease. Eslam M, Sanyal AJ, George J; International Consensus Panel. **Gastroenterology.** 2020 Feb 8. pii: S0016-5085(20)30171-2. doi: 10.1053/j.gastro.2019.11.312. [Epub ahead of print]. **International Consensus Panel:** Arun Sanyal, Brent Neuschwander-Tetri, Claudio Tiribelli, David E Kleiner, Elizabeth Brunt, Elisabetta Bugianesi, Hannele Yki-Järvinen, Henning Grønbaek, Helena Cortez-Pinto, Jacob George, Jiangao Fan, Luca Valenti, Manal Abdelmalek, Manuel Romero-Gomez, Mary Rinella, Marco Arrese, Mohammed Eslam, Pierre Bedossa, Philip N Newsome, Quentin M Anstee, Rajiv Jalan, Ramon Bataller, Rohit Loomba, Silvia Sookoian, Shiv K Sarin, Stephen Harrison, Takumi Kawaguchi, Vincent Wai-Sun Wong, Vlad Ratziu, Yusuf Yilmaz, Zobair Younossi.
- Estimation of Renin-Angiotensin-Aldosterone-System (RAAS)-Inhibitor effect on COVID-19 outcome: A Meta-analysis. Pirola CJ, **Sookoian S.** *J Infect.* 2020;81(2):276-281.
- Epigenetic factors in non-alcoholic fatty liver disease. Pirola CJ, **Sookoian S.** *Expert Rev Gastroenterol Hepatol.* 2020 Jun 1:1-16. doi: 10.1080/17474124.2020.1765772. Online ahead of print.
- Systematic Review with Meta-Analysis: The Significance of Histological Disease Severity in Lean Patients with Nonalcoholic Fatty liver Disease. Sookoian S, Pirola CJ. **Alimentary Pharmacology & Therapeutics.** 2017, 2018 Jan;47(1):16-25
- Genetics meets Therapy? Exome-wide association study reveals a loss-of-function variant in HSD17B13 (17-beta-hydroxysteroid dehydrogenase 13) that protects patients from liver damage and NAFLD-progression. Sookoian, Si, Arrese, M, Pirola CJ. **Hepatology.** 2018 DOI:10.1002/hep.30209.

- The dual and opposite role of the TM6SF2-rs58542926 Variant in Protecting against Cardiovascular Disease and Conferring Risk for Non-alcoholic fatty liver: A meta-analysis. Pirola CJ and Sookoian S. **Hepatology** **2015**; 62 (1742-1756).
- Noninvasive biomarkers in NAFLD and NASH - current progress and future promise. Wong VW, Adams LA, de Lédinghen V, Wong GL, **Sookoian S**. *Nat Rev Gastroenterol Hepatol*. 2018 May 29. doi: 10.1038/s41575-018-0014-9. [Epub ahead of print] Review
- Nonalcoholic Fatty Liver Disease and Metabolic Syndrome: Shared-Genetic basis of Pathogenesis. **Sookoian S** and Pirola CJ. **Hepatology** 2016 Nov;64(5):1417-1420.
- How safe is Moderate Alcohol Consumption in Overweight and Obese Individuals?" Gastroenterology's special 14th issue, "Commonalities and Distinctions Between Alcoholic and Nonalcoholic Fatty Liver Disease". Sookoian S and Pirola C. **GASTROENTEROLOGY** **2016** 150(8):1698-1703
- Nonalcoholic fatty liver disease. Brunt E, Wong V, Bugianesi E, Day C, Sookoian S Maher J, Neuschwander-Tetri B, Nobili V, Sirlin C, Rinella M. **Nature Reviews Disease Primers** 2015;1:15080. doi: 10.1038/nrdp.2015.80.
- NAFLD: Metabolic make-up of NASH: from fat and sugar to amino acids. Sookoian S, Pirola CJ. **Nat Rev Gastroenterol Hepatol**. **2014** Apr;11(4):205-7. Research Highlights
- PNPLA3, the history of an orphan gene of the potato tuber protein family that found an organ: the Liver. Sookoian S, Pirola CJ. **Hepatology**. 2014 Jun;59(6):2068-71
- Genome-wide Association Study of Liver-related Enzymes Suggests Putative Pleiotropic Effects on Diverse Traits and Diseases. Kim HS, **Sookoian S**, Hernaez R. *Hepatology*. 2021 Dec;74(6):3529-3533.
- PNPLA3 and COVID-19 outcomes: Thinking outside the box might explain the biology behind pleiotropic effects of rs738409 on the immune system. Pirola CJ, **Sookoian S**. *Liver Int*. 2021 Nov;41(11):2801-2804
- Editorial: bariatric surgery to reduce the risk of liver cancer. Pirola CJ, **Sookoian S**. *Aliment Pharmacol Ther*. 2021 May;53(10):1155-1156
- Alcohol consumption and metabolic syndrome: Clinical and epidemiological impact on liver disease. Åberg F, Byrne CD, Pirola CJ, Männistö V, **Sookoian S**. *J Hepatol*. 2022 Sep 5:S0168-8278(22)03061-6
- Geographical similarity and differences in the burden and genetic predisposition of NAFLD. Yip TC, Vilar-Gomez E, Petta S, Yilmaz Y, Wong GL, Adams LA, de Lédinghen V, **Sookoian S**, Wong VW. *Hepatology*. 2022 Sep 5. doi: 10.1002/hep.32774. Online ahead of print

Complete List of Published Work in My Bibliography

<https://pubmed.ncbi.nlm.nih.gov/?term=Sookoian+S&sort=date>

. Research Support

Ongoing Research Support (*Uninterrupted funding since 2003 by Agency for Scientific and Technological Research. Argentina*).

1. PICT 2019/ 0528 Sookoian S (PI) -Active. Genetics of NAFLD and its association with intrahepatic microbiome.
2. PICT 2018/889 Sookoian S (PI) -Active. INTRA-HEPATIC VASCULAR DISORDERS IN FATTY LIVER DISEASE AND ITS IMPACT ON THE EVOLUTION OF THE DISEASE. Agency for Scientific and Technological Research. Argentina. Consolidated Task Category. Role: Leader PI
3. PUE-2018 22920170100055CO Pirola CJ (PI) Sookoian S—Active. Biomarkers in liquid biopsy: towards personalized medicine. Rol: Co-Director

Completed Research Support (selected last 5 years)

1. PICT 2014/432 Sookoian S (PI). TRANSCRIPTOMICS AND DISEASE PROGRESSION IN NONALCOHOLIC FATTY LIVER DISEASE. Agency for Scientific and Technological. Argentina. Consolidated Task Category. Role: Leader PI.
2. PICT 2012/159 Sookoian S (PI). LIVER METABOLIC PROGRAMMING AND EPIGENETIC MODIFICATIONS. Agency for Scientific and Technological Research Research. Argentina. Consolidated Task Category. Role: Leader PI.
PICT 2011/441 Pirola CJ (PI). Micro RNAs (miRNAs): A NEW SYSTEM IN SIMILAR-ENDOCRINE PHYSIOLOGY AND PATHOPHYSIOLOGY OF METABOLIC SYNDROME. Agency for Scientific and Technological Research. Argentina. CONSOLIDATED GROUPS PICT 2011 Bicentennial INTERNATIONALLY. Role: Project co-Leader PI.
3. PICT 2015/551 Sookoian S (PI) -Active. Mitochondrial DNA variability and NAFLD pathogenesis. Agency for Scientific and Technological Research. Argentina. Consolidated Task Category. Role: Leader PI

Completed Research Support (International Cooperation)

1. Scientific Exchange in the context of International Cooperation Agreements (NSF-CONICET), Res. 1038 Division of Gastroenterology, Hepatology and Nutrition, Department of Internal Medicine, Virginia Commonwealth University School of Medicine, Richmond, VA 23298, USA. Prof Dr. Arun Sanyal. "Molecular determinant of disease progression of Non-alcoholic steatohepatitis". 2013-2014. Role: PI Argentina.
2. Department of Physiology, University of Murcia. Dr. Garaulet Marta. Project: Cronobiologia de la Obesidad. 2012. Spain. Role: Collaborator.
3. The Framingham Heart Study, Framingham, MA; The Center for Population Studies, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda. Dr. Daniel Levy. Project: Metabolomic Signatures of Metabolic Risk Factors. Role: Collaborator.
4. Departamento de Gastroenterología, Pontificia Universidad Católica de Chile, Santiago, Chile. Dr. Marco Arrese. Proyecto: Exploring new pathophysiological pathways in Non alcoholic fatty liver disease". Rol: International Researcher collaborator. FONDECYT 1110455. 2012-2016. Role: Collaborator
5. Medical Department. Genomic Gastroenterology. University Hospital Schleswig-Holstein, Campus Kiel. Schittenhelmstr.12D-24105 Kiel, Germany. Dr. Jochen Hampe. Project: Genome-wide studies on gallstone risk. 2009-2010. Role: Collaborator.
6. Department of Medicine, Indiana University School of Medicine, Indianapolis, Indiana, USA. Dr. Naga Chalasani. Proyecto: Genetics of NAFLD. Financiado con fondos de la contraparte en USA.
7. McDonnell International Scholars Academy. Global Incubator Seed Grants. 2021.